LabCorp/$LH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About LabCorp
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
Ticker
$LH
Sector
Primary listing
NYSE
Employees
65,450
Headquarters
Website
LabCorp Metrics
BasicAdvanced
$24B
31.29
$9.07
0.83
$2.88
1.02%
Price and volume
Market cap
$24B
Beta
0.83
52-week high
$289.20
52-week low
$209.38
Average daily volume
507K
Dividend rate
$2.88
Financial strength
Current ratio
1.504
Quick ratio
1.076
Long term debt to equity
69.655
Total debt to equity
77.783
Dividend payout ratio (TTM)
31.71%
Interest coverage (TTM)
5.44%
Profitability
EBITDA (TTM)
1,822.9
Gross margin (TTM)
28.14%
Net profit margin (TTM)
5.66%
Operating margin (TTM)
9.15%
Effective tax rate (TTM)
21.53%
Revenue per employee (TTM)
$210,000
Management effectiveness
Return on assets (TTM)
4.44%
Return on equity (TTM)
9.26%
Valuation
Price to earnings (TTM)
31.293
Price to revenue (TTM)
1.759
Price to book
2.78
Price to tangible book (TTM)
-14.95
Price to free cash flow (TTM)
18.797
Free cash flow yield (TTM)
5.32%
Free cash flow per share (TTM)
15.093
Dividend yield (TTM)
1.02%
Forward dividend yield
1.02%
Growth
Revenue change (TTM)
7.98%
Earnings per share change (TTM)
72.08%
3-year revenue growth (CAGR)
-1.68%
10-year revenue growth (CAGR)
6.69%
3-year earnings per share growth (CAGR)
-24.38%
10-year earnings per share growth (CAGR)
6.90%
3-year dividend per share growth (CAGR)
58.74%
What the Analysts think about LabCorp
Analyst ratings (Buy, Hold, Sell) for LabCorp stock.
Bulls say / Bears say
Labcorp reported second-quarter revenue of $3.53 billion, a 9.5% year-over-year increase that beat analysts' expectations, highlighting strong demand for its diagnostic testing services. (Reuters)
On July 24, 2025, Labcorp raised its full-year 2025 adjusted EPS guidance to $16.05–16.50 per share and lifted its revenue growth outlook for both diagnostic lab and biopharma services units, reflecting management’s confidence in the fundamental strength of the business. (Reuters)
After surpassing Q4 estimates, Labcorp projected 2025 revenues of $13.88–14.05 billion compared to the $13.8 billion consensus, indicating sustained demand across its core diagnostic and biopharma segments. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 1 Oct 2025.
LabCorp Financial Performance
Revenues and expenses
LabCorp Earnings Performance
Company profitability
LabCorp News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
FAQs
What’s the current market cap for LabCorp stock?
LabCorp (LH) has a market cap of $24B as of October 17, 2025.
What is the P/E ratio for LabCorp stock?
The price to earnings (P/E) ratio for LabCorp (LH) stock is 31.29 as of October 17, 2025.
Does LabCorp stock pay dividends?
Yes, the LabCorp (LH) stock pays dividends to shareholders. As of October 17, 2025, the dividend rate is $2.88 and the yield is 1.02%. LabCorp has a payout ratio of 31.71% on a trailing twelve-month basis.
When is the next LabCorp dividend payment date?
The next LabCorp (LH) dividend payment is scheduled for December 11, 2025.
What is the beta indicator for LabCorp?
LabCorp (LH) has a beta rating of 0.83. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.